Genenta Science SpA ADR (GNTA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Genenta Science SpA ADR (GNTA) has a cash flow conversion efficiency ratio of -0.077x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.69 Million) by net assets ($21.84 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Genenta Science SpA ADR balance sheet quality to measure how much of total assets are equity-financed.
Genenta Science SpA ADR - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Genenta Science SpA ADR's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore Genenta Science SpA ADR (GNTA) debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Genenta Science SpA ADR Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Genenta Science SpA ADR ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Climeon AB (publ)
ST:CLIME-B
|
-0.070x |
|
DE&T Co. Ltd
KQ:079810
|
0.028x |
|
Nexen Tire Prf 1
KO:002355
|
0.034x |
|
Dev Information Technology Limited
NSE:DEVIT
|
0.054x |
|
Enzo Biochem Inc
NYSE:ENZ
|
-0.074x |
|
Sensen Networks Ltd
AU:SNS
|
-0.184x |
|
BR.SCH.ED.HLD.SP.ADR CL.A
F:BSK0
|
N/A |
|
Baid Finserv Limited
NSE:BAIDFIN
|
0.008x |
Annual Cash Flow Conversion Efficiency for Genenta Science SpA ADR (2019–2025)
The table below shows the annual cash flow conversion efficiency of Genenta Science SpA ADR from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see GNTA company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $21.84 Million | $-6.87 Million | -0.314x | +37.03% |
| 2024-12-31 | $12.50 Million | $-6.24 Million | -0.499x | +8.94% |
| 2023-12-31 | $20.43 Million | $-11.21 Million | -0.548x | -130.19% |
| 2022-12-31 | $31.14 Million | $-7.42 Million | -0.238x | -33.05% |
| 2021-12-31 | $38.86 Million | $-6.96 Million | -0.179x | +55.12% |
| 2020-12-31 | $15.15 Million | $-6.04 Million | -0.399x | -202.01% |
| 2019-12-31 | $18.85 Million | $-2.49 Million | -0.132x | -- |
About Genenta Science SpA ADR
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for us… Read more